This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
North Chicago, IL-based AbbVie has become one of the top-most pharma companies after it acquired Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. The deal is expected to transform AbbVie’s portfolio and lower its dependence on Humira, its flagship product, which has already lost patent protection in Europe and is due to face biosimilar competition in the United States in 2023. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib) position it well for long-term growth.
AbbVie (ABBV) Stock Hits 52-Week High: More Room to Run?
by Zacks Equity Research
AbbVie Inc. (ABBV) shares hit a 52-week high of $71.12 on Friday before eventually closing at $71.05.
Novartis (NVS) Announced Positive Data on Psoriasis Cosentyx
by Zacks Equity Research
Novartis AG (NVS) announced positive data on arthritis drug Cosentyx from two phase III studies.
Biotech Stock Roundup: Management Changes at Biogen, Alexion, GILD Files HIV Drug
by Arpita Dutt
Key highlights in the biotech sector include management changes for Biogen (BIIB) and Alexion as well as a regulatory filing for Gilead's HIV regimen.
AbbVie (ABBV) Announced Positive Phase III RA Candidate Data
by Zacks Equity Research
AbbVie Inc. (ABBV) announced positive top-line results from a phase III study on rheumatoid arthritis candidate, upadacitinib (ABT-494).
Novartis Biosimilar Pipeline, 2018 Growth Plans on Track
by Zacks Equity Research
Novartis AG (NVS) announced that the EMA has accepted its applications for biosimilar versions of AbbVie's (ABBV) Humira (adalimumab) and Johnson & Johnson's (JNJ) Remicade (infliximab) for review.
Biotech Stock Roundup: Puma Soars on Advisory Panel Vote, Priority Review for Kite Drug
by Arpita Dutt
Key highlights in the biotech sector include a favorable advisory panel vote for Puma (PBYI) and positive data and positive data from companies like Inovio and BioCryst.
Biogen's Fampyra Conditional Approval Converted to Standard
by Zacks Equity Research
Biogen Inc. (BIIB) announced that the conditional marketing authorization for its drug Fampyra for improvement of walking in multiple sclerosis (MS) patients in the EU has been converted to a standard marketing approval.
The Zacks Analyst Blog Highlights: Boeing, AbbVie, UnitedHealth, Consolidated Edison and Cisco
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Boeing, AbbVie, UnitedHealth, Consolidated Edison and Cisco
AbbVie Down on Humira Patent Loss: Is More Damage in Store?
by Zacks Equity Research
AbbVie Inc.'s (ABBV) shares declined more than 2% on Wednesday after it lost a lawsuit related to a patent protecting its key rheumatoid arthritis drug, Humira to small biotech Coherus BioSciences, Inc. (CHRS),
New Stock Research Reports for Boeing, AbbVie and UnitedHealth
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Boeing (BA), AbbVie (ABBV) and UnitedHealth (UNH).
Celgene's (CELG) Revlimid Looks Solid on Label Expansion
by Zacks Equity Research
Celgene's key growth driver, Revlimid, continues to outperform on the back of market share gains and increased duration.
AbbVie and J&J Present Positive Imbruvica Leukemia Data
by Zacks Equity Research
AbbVie Inc. (ABBV) recently announced positive data from a pooled analysis of three phase III studies evaluating its cancer drug, Imbruvica (ibrutinib).
Infinity (INFI) Reports Narrower-than-Expected Loss in Q1
by Zacks Equity Research
Infinity Pharmaceuticals, Inc. (INFI) reported a loss of 21 cents per share in first-quarter 2017, narrower than the Zacks Consensus Estimate loss of 22 cents. Also, the company had reported loss of 82 cents in the year-ago quarter.
Biotech Stock Roundup: Regeneron, BioMarin Report Q1, Kite Down on Patient Death
by Arpita Dutt
Kite's (KITE) shares were hit by news regarding a patient death resulting from cerebral edema.
Gilead (GILD) Beats on Q1 Earnings, Revenues Miss Estimates
by Zacks Equity Research
Gilead Sciences, Inc.'s (GILD) first-quarter 2017 earnings (including the impact of stock-based compensation expenses) of $2.20 per share beat the Zacks Consensus Estimate of $2.18.
AbbVie (ABBV) Q1 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
AbbVie Inc. (ABBV) reported better-than-expected results in the first-quarter of 2017. The company surpassed both earnings and sales expectations.
AbbVie (ABBV) Beats Earnings and Revenue in Q1
by Zacks Equity Research
AbbVie's first-quarter earnings came in at $1.28 per share, beating the Zacks Consensus Estimate of $1.26.
5 Fantastic Earnings Charts
by Tracey Ryniec
Tracey brings you the companies with the best earnings charts each week.
Pharma Stocks Q1 Earnings Roster for Apr 27: CELG, ABBV, BMY
by Zacks Equity Research
Celgene, AbbVie and Bristol-Myers Squibb are expected to report earnings on Apr 27.
Gilead (GILD) Q1 Earnings: Stock Likely to Beat Estimates?
by Zacks Equity Research
Gilead Sciences Inc. (GILD) is scheduled to report first-quarter 2017 results on May 2, after the market closes.
Biogen (BIIB) Q1 Earnings & Sales Top, Spinraza Sales Strong
by Zacks Equity Research
Biogen Inc. (BIIB) reported better-than-expected results in the first-quarter of 2017. The company surpassed expectations both for earnings and sales.
AbbVie (ABBV) Presents Positive Data on HCV Combination Drug
by Zacks Equity Research
AbbVie Inc. (ABBV) announced that data from two phase III studies, EXPEDITION-1 and ENDURANCE-3, evaluating its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P) for all genotypes of Hepatitis C virus (HCV)
What's in Store for AbbVie (ABBV) this Earnings Season?
by Zacks Equity Research
AbbVie Inc. (ABBV) is slated to release first-quarter 2017 earnings, before the opening bell on Apr 27.
What's in Store for Biogen (BIIB) this Earnings Season?
by Zacks Equity Research
Biogen Inc. (BIIB), a well-known name in the multiple sclerosis (MS) market, will report first-quarter 2017 results on Apr 25, before the market opens.
AbbVie's (ABBV) Cancer Candidate Fails in Phase III Studies
by Zacks Equity Research
AbbVie Inc. announced disappointing top-line results from two phase III studies evaluating veliparib in combination with chemotherapy for treatment of patients with squamous non-small cell lung cancer and triple negative breast cancer.